Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a r… Read more
Castle Biosciences Inc (CSTL) - Net Assets
Latest net assets as of September 2025: $467.05 Million USD
Based on the latest financial reports, Castle Biosciences Inc (CSTL) has net assets worth $467.05 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($562.79 Million) and total liabilities ($95.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $467.05 Million |
| % of Total Assets | 82.99% |
| Annual Growth Rate | N/A |
| 5-Year Change | 9.66% |
| 10-Year Change | N/A |
| Growth Volatility | 154.48 |
Castle Biosciences Inc - Net Assets Trend (2017–2024)
This chart illustrates how Castle Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Castle Biosciences Inc (2017–2024)
The table below shows the annual net assets of Castle Biosciences Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $455.83 Million | +16.50% |
| 2023-12-31 | $391.27 Million | -1.97% |
| 2022-12-31 | $399.15 Million | -3.06% |
| 2021-12-31 | $411.74 Million | -0.95% |
| 2020-12-31 | $415.69 Million | +388.40% |
| 2019-12-31 | $85.11 Million | +945.28% |
| 2018-12-31 | $-10.07 Million | +29.44% |
| 2017-12-31 | $-14.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Castle Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14900441600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.00K | 0.01% |
| Other Comprehensive Income | $230.00K | 0.05% |
| Other Components | $655.70 Million | 143.85% |
| Total Equity | $455.83 Million | 100.00% |
Castle Biosciences Inc Competitors by Market Cap
The table below lists competitors of Castle Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Guyuelongshan Shaoxing Wine Co Ltd
SHG:600059
|
$696.96 Million |
|
Hsino Tower Group Co., Ltd.
SHG:601096
|
$697.19 Million |
|
Hangzhou XZB Tech Co Ltd
SHG:603040
|
$697.24 Million |
|
Itcen Co. Ltd
KQ:124500
|
$697.59 Million |
|
AEHR TEST SYSTEMS DL-01
F:AYB
|
$696.69 Million |
|
Regis Healthcare Ltd
AU:REG
|
$696.47 Million |
|
Mavi Giyim Sanayi Ve Ticaret AS
IS:MAVI
|
$696.30 Million |
|
Zhejiang Jiaao Enprotech
SHG:603822
|
$696.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Castle Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 391,269,000 to 455,835,000, a change of 64,566,000 (16.5%).
- Net income of 18,245,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 94,000.
- Other factors increased equity by 46,227,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $18.25 Million | +4.0% |
| Other Comprehensive Income | $94.00K | +0.02% |
| Other Changes | $46.23 Million | +10.14% |
| Total Change | $- | 16.50% |
Book Value vs Market Value Analysis
This analysis compares Castle Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.66x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-1.46 | $25.90 | x |
| 2018-12-31 | $-0.95 | $25.90 | x |
| 2019-12-31 | $9.83 | $25.90 | x |
| 2020-12-31 | $21.96 | $25.90 | x |
| 2021-12-31 | $16.38 | $25.90 | x |
| 2022-12-31 | $15.32 | $25.90 | x |
| 2023-12-31 | $14.60 | $25.90 | x |
| 2024-12-31 | $15.58 | $25.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Castle Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.49%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.17x
- Recent ROE (4.00%) is above the historical average (-3.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -89.93% | 1.40x | 0.00x | $-10.94 Million |
| 2018 | 0.00% | -27.94% | 1.02x | 0.00x | $-5.36 Million |
| 2019 | 6.20% | 10.17% | 0.43x | 1.41x | $-3.23 Million |
| 2020 | -2.47% | -16.42% | 0.14x | 1.06x | $-51.85 Million |
| 2021 | -7.60% | -33.26% | 0.20x | 1.12x | $-72.47 Million |
| 2022 | -16.82% | -48.99% | 0.31x | 1.12x | $-107.05 Million |
| 2023 | -14.69% | -26.15% | 0.48x | 1.16x | $-96.59 Million |
| 2024 | 4.00% | 5.49% | 0.63x | 1.17x | $-27.34 Million |
Industry Comparison
This section compares Castle Biosciences Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Castle Biosciences Inc (CSTL) | $467.05 Million | 0.00% | 0.20x | $696.70 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |